PORTFOLIO NEWS eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 8, 2023 Read More » ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) August 4, 2023 Read More » NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights August 3, 2023 Read More » Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital August 1, 2023 Read More » Neurona Therapeutics Appoints James Stutz as Chief Financial Officer and Chief Business Officer July 31, 2023 Read More » Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies July 27, 2023 Read More » Circle Pharma Strengthens Its Executive Leadership Team With Two Senior Appointments in Clinical Development July 26, 2023 Read More » Circle Pharma Achieves Major Milestone with the Selection of a Clinical Development Candidate Directly Inhibiting Cyclins A and B July 19, 2023 Read More » Atavistik Bio Appoints Bryan Stuart as Chief Executive Officer July 17, 2023 Read More » Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update July 13, 2023 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 8, 2023 Read More »
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) August 4, 2023 Read More »
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights August 3, 2023 Read More »
Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital August 1, 2023 Read More »
Neurona Therapeutics Appoints James Stutz as Chief Financial Officer and Chief Business Officer July 31, 2023 Read More »
Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies July 27, 2023 Read More »
Circle Pharma Strengthens Its Executive Leadership Team With Two Senior Appointments in Clinical Development July 26, 2023 Read More »
Circle Pharma Achieves Major Milestone with the Selection of a Clinical Development Candidate Directly Inhibiting Cyclins A and B July 19, 2023 Read More »
Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update July 13, 2023 Read More »
